A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a phase III clinical trial for metastatic pancreatic ductal adenocarcinoma.
Research published in April in the Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
